Ikena Oncology, Inc. IKNA
Set alert
17.16 0.00 0.00%
At close · Jul 25
1.36 Day range 17.16
1.22 52-week range 2.29
- Open
- 1.38
- Prev close
- 17.16
- Mkt cap
- 80.59M
- Vol
- 457.26K
- Avg vol
- 72.44K
- EPS
- -1.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.36
- High
- 17.16
- Forward P/E
- -1.96
- Beta
- 0.48
- Short ratio
- 1.23
- Inst. own
- 63.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.69
- 200-d avg
- 1.60
- 1y target
- 3.00
Key statistics
- Market cap
- 80.59M
- Enterprise value
- -54.84M
- Trailing P/E
- 0.00
- Forward P/E
- -1.96
- PEG ratio
- 0.00
- Price / sales
- 122.29
- Price / book
- 0.60
- EPS (TTM)
- -1.23
- Beta
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 659.00K
- Revenue growth
- 0.00%
- Free cash flow
- -43.97M
- Total cash
- 138.03M
- Total debt
- 8.39M
- Return on equity
- -37.09%
- Shares outstanding
- 48.26M
- Short % of float
- 0.24%
- 50-day average
- 1.69
- 200-day average
- 1.60
Analyst view
Consensus: none
Price target (mean) 3.00 -82.5% downside
Now 17.16
- Target (low)
- 2.00
- Target (mean)
- 3.00
- Target (high)
- 4.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.17.
Financials — quick view
IKNA Revenue — quarterly 0
IKNA Net income — quarterly -2.77M
IKNA EPS — quarterly -0.72
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.27 | -0.19 | +0.08 | +29.63% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | -0.27 | +0.04 | +12.90% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.40 | -0.28 | +0.12 | +30.00% |
| May 13, 2024 | Mar 1, 2024 | -0.40 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | -0.41 | -0.41 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 29, 2024 | Wedbush | down | Outperform | Neutral |
| May 29, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 14, 2024 | Wedbush | reit | Outperform | Outperform |
| Mar 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Ikena Oncology, Inc.
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ikenaoncology.com
News
- Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
- Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
- Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
- Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
- Ikena Oncology Reports Third Quarter 2024 Financial Results
- Ikena Oncology Reports Second Quarter 2024 Financial Results
- Best Momentum Stocks to Buy for July 12th
Your note
Sign in to keep a note on IKNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONITA DAVID P. M.D. | Director | Stock Award(Grant) | Aug 3, 2023 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Stock Award(Grant) | Aug 3, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 20.53% | 9,907,945 | 16.55M | Sep 29, 2024 |
| Atlas Venture Life Science Advisors, LLC | 10.40% | 5,018,178 | 8.38M | Sep 29, 2024 |
| BVF Inc. | 9.88% | 4,769,164 | 7.96M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 8.48% | 4,091,118 | 6.83M | Sep 29, 2024 |
| Omega Fund Management, Llc | 4.66% | 2,249,123 | 3.76M | Sep 29, 2024 |
| Vanguard Group Inc | 2.87% | 1,384,664 | 2.31M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.18% | 1,051,228 | 1.76M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.66% | 318,152 | 531.31K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.28% | 134,420 | 224.48K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 100,000 | 167.00K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.13% | 62,748 | 104.79K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.11% | 51,100 | 85.34K | Sep 29, 2024 |